TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38970713

Group type: EXPERIMENTAL
Intervention: No abdominal drain and no prolonged antibiotic prophylaxis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Abdominal drain and prolonged antibiotic prophylaxis
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Radical right colectomy (RRC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard D2 dissection
Number of subjects: 36
Study: 38971151

Group type: EXPERIMENTAL
Intervention: Neoadjuvant monotherapy with the PARP inhibitor (PARPi) niraparib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapies
Number of subjects: 100
Study: 38971175

Group type: EXPERIMENTAL
Intervention: BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone)
Number of subjects: 1482

Group type: COMPARATOR
Intervention: eBEACOPP
Number of subjects: 1482
Study: 38971202

Group type: EXPERIMENTAL
Intervention: DBIP-ESD
Number of subjects: 140

Group type: COMPARATOR
Intervention: T-ESD
Number of subjects: 140
Study: 38971385

Group type: EXPERIMENTAL
Intervention: Personalized response-based adaptive radiation therapy (RT) with concurrent chemoradiation therapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Personalized response-based adaptive radiation therapy (RT)
Number of subjects: 47
Study: 38971424

Group type: EXPERIMENTAL
Intervention: Pecan-containing meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Energy- and macronutrient-matched control meal
Number of subjects: 0
Study: 38971633

Group type: EXPERIMENTAL
Intervention: Sunflower oil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Silicone-based spray
Number of subjects: 86
Study: 38971713

Group type: EXPERIMENTAL
Intervention: Digital guideline support
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 204

Group type: COMPARATOR
Intervention: Expert approach
Number of subjects: 204
Study: 38971743

Group type: EXPERIMENTAL
Intervention: Risk management program including professional e-learning training, identification of a risk management advisor, and multidisciplinary meetings.
Number of subjects: 401

Group type: COMPARATOR
Intervention: Control arm (no intervention).
Number of subjects: 401
Study: 38971756

Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control (no in-line filtration)
Number of subjects: 736
Study: 38971950

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg on Day 1 every 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rucaparib plus Atezolizumab
Number of subjects: 0
Study: 38972091

Group type: EXPERIMENTAL
Intervention: Safe Brain Initiative care bundle (SBI-CB) including 18 delirium-reducing recommendations, patient education, staff training, coordination meetings, and outcome monitoring in the PACU.
Number of subjects: 18697

Group type: EXPERIMENTAL
Intervention: Initial POD incidence in the PACU after the first three months was 16.36% (n = 1021).
Number of subjects: 18697
Study: 38972306

Group type: EXPERIMENTAL
Intervention: Ferric Citrate (FC)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 209
Study: 38972465

Group type: EXPERIMENTAL
Intervention: SBPT (38 Gy in 5 fractions)
Number of subjects: 135

Group type: COMPARATOR
Intervention: CFPT (79.2 Gy in 44 fractions)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: SBPT
Number of subjects: 135

Group type: COMPARATOR
Intervention: SBPT and CFPT
Number of subjects: 135
Study: 38972535

Group type: EXPERIMENTAL
Intervention: Post-PCI heparin
Number of subjects: 4088

Group type: EXPERIMENTAL
Intervention: Higher hourly dose or total doses of heparin
Number of subjects: 4088

Group type: COMPARATOR
Intervention: No post-PCI heparin
Number of subjects: 4088
Study: 38972612

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (400 mg dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daily consumption of 2 × 400 mg of nitrate over 4 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 15
Study: 38972617

Group type: EXPERIMENTAL
Intervention: Prolonged and repeated microemboli detection using bilateral stationary TCDM for one hour followed by unilateral ambulatory TCDM for two hours, repeated for two days and after three months
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Initial microemboli detection
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Prolonged and repeated microemboli detection
Number of subjects: 47
Study: 38972831

Group type: EXPERIMENTAL
Intervention: Cytoreductive prostatectomy with systemic therapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Cytoreductive prostate radiotherapy or ablation with systemic therapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Additional cytoreductive treatment
Number of subjects: 352
Study: 38972960

Group type: EXPERIMENTAL
Intervention: CF-LI-guided pulmonary vein isolation (PVI)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: CF-LI-guided PVI
Number of subjects: 275
Study: 38972988

Group type: EXPERIMENTAL
Intervention: Combined program of physical exercise and cognitive training (experimental group, EG)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Cognitive stimulation (control group, CG)
Number of subjects: 95
Study: 38973149

Group type: EXPERIMENTAL
Intervention: Smokers (n=23)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Non-smokers (n=92)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Smokers (RA patients, n=38)
Number of subjects: 205
Study: 38973793

Group type: EXPERIMENTAL
Intervention: Coil localization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anchored needle (AN) localization
Number of subjects: 100
Study: 38974112

Group type: EXPERIMENTAL
Intervention: Training using the SBAR/SAED tool and standard instructions for managing respiratory distress/dyspnea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard instructions only
Number of subjects: 0
Study: 38974350

Group type: EXPERIMENTAL
Intervention: Parenteral thiamine (100 mg daily for ≥3 d)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Community comparison group (matched by age, sex, and residence)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Thiamine biomarkers
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: ThDP
Number of subjects: 287
Study: 38974656

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38974817

Group type: EXPERIMENTAL
Intervention: Expiratory pulmonary venous volume
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) quantitative pulmonary vessel morphology
Number of subjects: 138
Study: 38974920

Group type: EXPERIMENTAL
Intervention: Mentalization Breakdown Interview (MBI-RF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Adult Attachment Interview (AAI-RF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MBI-RF
Number of subjects: 45

Group type: COMPARATOR
Intervention: AAI-RF
Number of subjects: 45
Study: 38974930

Group type: EXPERIMENTAL
Intervention: Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)
Number of subjects: 20
Study: 38975122

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study: 38975302

Group type: EXPERIMENTAL
Intervention: l-oxiracetam
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: oxiracetam
Number of subjects: 590

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 590
Study: 38975624

Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Number of subjects: 2
Study: 38975711

Group type: EXPERIMENTAL
Intervention: L-tyrosine (2000 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: L-theanine (200 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 38976019

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 45
Study: 38976035

Group type: EXPERIMENTAL
Intervention: PSMA-targeted positron emission tomography (PET-CT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-of-care imaging (CT/bone scan)
Number of subjects: 20
Study: 38976096

Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 63
Study: 38976126

Group type: EXPERIMENTAL
Intervention: SB11 Pre-filled Syringe (PFS) administered at a dosage of 0.5 mg via intravitreal injection (IVT).
Number of subjects: 34
Study: 38976265

Group type: EXPERIMENTAL
Intervention: 24-mg dose of a weekly extended-release formulation of buprenorphine (CAM2038)
Number of subjects: 100
Study: 38976270

Group type: EXPERIMENTAL
Intervention: VMP 200 mg twice a day
Number of subjects: 129

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: VMP 200 mg twice a day (twin pregnancies)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No treatment (twin pregnancies)
Number of subjects: 129
Study: 38976321

Group type: EXPERIMENTAL
Intervention: Experimental app with additional content tailored for PAQS and those with HIV
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care control app
Number of subjects: 19
Study: 38976363

Group type: EXPERIMENTAL
Intervention: Cilofexor 30 mg (weeks 1-4), 60 mg (weeks 5-8), 100 mg (weeks 9-12)
Number of subjects: 11
Study: 38976448

Group type: EXPERIMENTAL
Intervention: Zastaprazan 20 mg once daily for 8 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily for 8 weeks
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 38976481

Group type: EXPERIMENTAL
Intervention: Prenatal Mindfulness Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38976607

Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study: 38976641

Group type: EXPERIMENTAL
Intervention: Interventions that support the sharing of information on HIV among OPWH and caregivers
Number of subjects: 29
Study: 38976708

Group type: EXPERIMENTAL
Intervention: People with obesity and schizophrenia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: People with obesity and bipolar disorder
Number of subjects: 80

Group type: COMPARATOR
Intervention: People with obesity without mental disease or sleep disorders
Number of subjects: 80

Group type: COMPARATOR
Intervention: People without obesity, mental disease or sleep disorders
Number of subjects: 80
Study: 38976710

Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton intervention for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy for 12 weeks
Number of subjects: 0
Study: 38976993

Group type: EXPERIMENTAL
Intervention: Urine-test counselling group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care group
Number of subjects: 100
Study: 38977179

Group type: EXPERIMENTAL
Intervention: Self-sampling kit (SSK) offered by GP during consultation (Arm A)
Number of subjects: 3375

Group type: EXPERIMENTAL
Intervention: Self-sampling kit (SSK) sent with a personal GP signed invitation letter (Arm B)
Number of subjects: 3375

Group type: COMPARATOR
Intervention: Standard invitation letter from the Centre for Cancer Detection (Control Arm)
Number of subjects: 3375

Group type: EXPERIMENTAL
Intervention: Self-sampling kit (SSK) offered by GP (Arm A)
Number of subjects: 3375
Study: 38977276

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) in patients with history of uveitis
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo in patients with history of uveitis
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) in phase 2b/3 pool
Number of subjects: 586
Study: 38977298

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (3+1 schedule)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (2+1 schedule)
Number of subjects: 129
Study: 38977361

Group type: EXPERIMENTAL
Intervention: Brace treatment with a Pavlik harness for a minimum of 6 weeks
Number of subjects: 514

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 514
Study: 38977368

Group type: EXPERIMENTAL
Intervention: COACH intervention with enhanced alerts and displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: COACH without alerts and a simple display (Control)
Number of subjects: 0
Study: 38977430

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 147
Study: 38977536

Group type: EXPERIMENTAL
Intervention: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy and 20 mg of oral rosuvastatin once daily for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Doxorubicin for 4 cycles (3 months) followed by trastuzumab adjuvant therapy (control group)
Number of subjects: 50
Study: 38977651

Group type: EXPERIMENTAL
Intervention: ECAP dose-controlled closed-loop spinal cord stimulation (SCS)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Day 0 evaluation
Number of subjects: 132
Study: 38977653

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study: 38977655

Group type: EXPERIMENTAL
Intervention: High John Henryism (JH)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Low John Henryism (JH)
Number of subjects: 274
Study: 38977707

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RVd (control group)
Number of subjects: 0
Study: 38977715

Group type: EXPERIMENTAL
Intervention: Short mutated allele (40-45 CAG repeats) with normal alleles more than 17 CAG repeats
Number of subjects: 3723

Group type: EXPERIMENTAL
Intervention: Short mutated allele (40-45 CAG repeats)
Number of subjects: 3723

Group type: EXPERIMENTAL
Intervention: Normal alleles in higher half of length distribution (more than 17 CAG repeats)
Number of subjects: 3723
Study: 38977911

Group type: EXPERIMENTAL
Intervention: Calcium-free dialysate with calcium reinjection according to ionic dialysance (CFD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Heparin-coated membrane (HCM)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Calcium-free dialysate (CFD)
Number of subjects: 94
Study: 38977914

Group type: EXPERIMENTAL
Intervention: Supplemental MRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional breast density measures
Number of subjects: 0
Study: 38977983

Group type: EXPERIMENTAL
Intervention: Preoperative hyperglycemia (defined as ≥ 6.1mmol/L)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Preoperative glucose levels as a continuous variable
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Normal preoperative glucose levels
Number of subjects: 1440
Study: 38977995

Group type: EXPERIMENTAL
Intervention: Face-to-face traditional training group (TRHG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: General remote training group (GTHG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AI-based remote training group (AITHG)
Number of subjects: 75
Study: 38978009

Group type: EXPERIMENTAL
Intervention: Multidisciplinary medication review using STOPP criteria
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Multidisciplinary medication review using START criteria
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Clinical committee decisions on STOPP criteria
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Clinical committee decisions on START criteria
Number of subjects: 674
Study: 38978010

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D) patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: RNAseq analysis
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Functional enrichment analysis
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Downregulated gene sets
Number of subjects: 84
Study: 38978051

Group type: EXPERIMENTAL
Intervention: Observation alone (O)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Motor imagery with action observation (OI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Motor execution synchronized with action observation (OM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (C) - Passive observation
Number of subjects: 38
Study: 38978068

Group type: EXPERIMENTAL
Intervention: Baseline LUS aeration score
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Early deterioration of the LUS score
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Early change in the LUS aeration score
Number of subjects: 442
Study: 38978065

Group type: EXPERIMENTAL
Intervention: Universal testing and treatment (UTT) intervention
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Working as a community health worker (CHW)
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Witnessing stigmatizing behaviors towards people living with HIV among co-workers
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Higher educational attainment
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Greater years providing HIV services
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Testing negative for HIV at last HIV test
Number of subjects: 1499
Study: 38978089

Group type: EXPERIMENTAL
Intervention: Decolonization with octenisan® wash lotion 1× per day and octenisan® md nasal gel 2-3× per day for 5 days
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No decolonization (Control)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Decolonization
Number of subjects: 1000
Study: 38978119

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) therapy, 3 times a week for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celecoxib, 0.2 g/day oral for 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) therapy
Number of subjects: 60
Study: 38978117

Group type: EXPERIMENTAL
Intervention: Cardio-Metabolic Clinic treatment
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1500
Study: 38978124

Group type: EXPERIMENTAL
Intervention: CATT
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: HAT Sero-K-SeT
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Bioline HAT 2.0
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: DCN HAT RDT
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: HAT Sero-K-SeT 2.0
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Immunological laboratory tests
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Molecular laboratory tests
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Abbott Bioline HAT 2.0
Number of subjects: 1095

Group type: COMPARATOR
Intervention: HAT Sero-K-Set 2.0
Number of subjects: 1095
Study: 38978309

Group type: EXPERIMENTAL
Intervention: ACE inhibitors/ARBs use
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Higher haemoglobin
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Higher HbF
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Higher alkaline phosphatase
Number of subjects: 269
Study: 38978354

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin 10%
Number of subjects: 44
Study: 38978405

Group type: EXPERIMENTAL
Intervention: CAB+RPV LA administered every 2 months (Q2M)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CAB+RPV LA
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard arm (Arm-S)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enhanced arm (Arm-E)
Number of subjects: 70
Study: 38978403

Group type: EXPERIMENTAL
Intervention: TAF/emtricitabine (FTC)/DTG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate (TDF)/FTC/DTG
Number of subjects: 0

Group type: COMPARATOR
Intervention: TDF/FTC/efavirenz (EFV)
Number of subjects: 0
Study: 38978512

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (second dose administered at enrollment, day 1)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (first dose administered ≥1 year before enrollment)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (adverse events reported through 15 days after vaccination)
Number of subjects: 146
Study: 38978573

Group type: EXPERIMENTAL
Intervention: Personalized behavioral approach for dietary management
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Standardized behavioral intervention (one-size-fits-all dietary recommendations)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care control (UCC)
Number of subjects: 255
Study: 38978597

Group type: COMPARATOR
Intervention: Routine supplementation (400 IU/day with established feedings)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Increased supplementation (800 IU/day with any feedings)
Number of subjects: 180
Study: 38978605

Group type: EXPERIMENTAL
Intervention: AMBLE training (dorsiflexion assist-as-needed ankle robotics) for 9 hours (9 weeks × 2 sessions/week)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: AMBLE training
Number of subjects: 16
Study: 38978659

Group type: EXPERIMENTAL
Intervention: Household contact investigation (HCI)
Number of subjects: 39
Study: 38978673

Group type: EXPERIMENTAL
Intervention: IV GD2-CART (DL1=1e6/kg; DL2=3e6/kg) followed by ICV GD2-CART (10-30e6 GD2-CART)
Number of subjects: 11

Group type: COMPARATOR
Intervention: IV GD2-CART (DL2=3e6/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: ICV GD2-CART infusions
Number of subjects: 11
Study: 38978809

Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study: 38978814

Group type: EXPERIMENTAL
Intervention: Cardiac-related spinal cord motion measurements in MRI+ patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cardiac-related spinal cord motion measurements in MRI- patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Extent of spinal stenosis (aSCOR)
Number of subjects: 84
Study: 38979062

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (≥4 consecutive intravenous doses)
Number of subjects: 132
Study: 38979073

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Psychophysical therapy (received by 73% of AN participants)
Number of subjects: 68
Study: 38979608

Group type: EXPERIMENTAL
Intervention: ARRY-371797
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77